{"title": "PDF", "author": "PDF", "url": "https://docs.house.gov/meetings/IF/IF14/20140520/102237/HHRG-113-IF14-Wstate-SasinowskiF-20140520-SD005.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "Supporting Documents for Frank Sasinowski's May 20, 2014 Testimony Before House E&C Health Subcommittee Appendix 1: Proposed Advisory Committee Chart: Substantial Evidence of Effectiveness. Appendix 2: E-Filing on Regulations.Gov by Frank Sasinowski, Director, and Alexander VarondHyman, Phelps & McNamara, P.C. re: Docket No. FDA-2013-D-0575, Comment on Section VII. C.: \"Evidentiary Criteria for Accelerated Approval\" of the FDA \"Draft Guidance for Industry: Expedited Programs for Serious Conditions\u2014Drugs and Biologics\" (Aug. 26, 2013). Appendix 3: King et al., A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis , N. Eng. J. Med., NEJM.org DOI: 10.1056/NEJNMoa1402582 (May 2014). Appendix 4: Memorandum re Iloprost, NDA 21-779, Cotherix, Inc. from Robert Temple, Director, Office of Drug Evaluation I, CDER, FDA (Dec. 27, 2004). Appendix 5: Approvable Letter from Robert Temple, Office Director, Office of Drug Evaluation I, CDER, FDA, to Benjamin Lewis, Senior Director, Regulatory Affairs, Prestwick Pharmaceuticals, In. (Mar. 24, 2006). Appendix 6: Carl Peck & Jill Wechsler, Report of a Workshop on Confirmatory Evidence to Support a Single Clinical Trial as a Basis for New Drug Approval, 36 Drug Information Journal 517 (2002). Appendix 7: Frank Sasinowski, Quantum of Effectiveness Evidence in FDA's Approval of Orphan Drugs: Cataloging FDA's Flexibility in Regulating Therapies for Persons with Rare Disorders , 46 Drug Information Journal 238 (Mar. 2012).Appendix 1: Proposed Advisory Committee Chart Substantial Evidence of Effectiveness Quantum of Effectiveness Evidence Needed Source of Authority 1 Two Adequate and Well-Controlled Studies 21 U.S.C. \u00a7 355(d)1 2 \u00a7 355(d) as amended by FDAMA 1152 3 One Study Providing Statistically Very Persuasive Evidence and Where a Second Study Would be Difficult to Conduct on Practical or Ethical GroundsMay 1998 Guidance3 Types of Therapies in which FDA Has Exercised Flexibility AAccelerated Approval/Subpart H/Fast Track Therapies Historical FDA Precedents4 BOrphan Drug Therapies Historical FDA Precedents5 1.Federal Food, Drug, Cosmetic (FDC) Act \u00a7 Modernization Act \u00a7 115 3.FDA Guidance for Industry: Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products (May 1998) 4.FDC Act \u00a7 506 2 2 3 -1 13 2.Ferriprox 2 2 2 1 3 2 4 0 16 3.Makena 2 2 1 1 1 3 4 1 15 4.Promacca 2 2 2 0 2 1 4 1 14 S,Exjade 2 2 2 1 3 2 2 0 14 6Levaquin 2 2 1 1 3 2 4 1 16 7,Tysabri 2 2 2 0 2 3 4 1 16 B.Luveris 2 2 2 1 1 2 2 2 14 9.Fabrazyme 2 2 2 1 3 1 4 0 15 lo.Remodulin 2 2 2 1 3 1 3 1 15 liCipro 2 2 2 1 3 2 4 1. 17 12.Celebrex 2 2 2 1 3 3 4 0 17 13.Synercid 2 1 2 1 3 2 2 0 13 14,Remicade 2 2 2 1 1 1 3 0 12 1S.Priftin 2 2 2 1 2 2 2 0 13 16.Sullamylon 2 2 2 1 3 2 1 0 13 17ProAmaeine 1 2 2 0 3 2 3 0 13 18.Biaxin 2 1 2 1 2 1 2 1 12 19,Betaseron 2 2 2 1 2 2 forpharmaceutical/biotech 527 U CtU C C) Cd w DC U-E 0 F 0 I C\u2014ri\u2014rlrlrlrirlrirlrlrlrlflrflrtflrflr.flflo\u2014rt'0CNCC'C\u2014tt'tt,,t,t'1i-'t'fl'fl'0InniCCOC00\u20143C'Ln4.ta\u2014CCrJ \u2014CCCCCCC000000000000-J\u2014J-J-3-3\u20143_1_J-J-3C'C'C'0'0'a,'C'C'C'tjiCfl 0 3 m 0 \u20ac1 C, I-a LI, C0-o 3 V LI, r 3 "}